How we run ourselves

The Royal Marsden is managed by a Board of Directors made up of a Chairman, Chief Executive, four other Executive Directors, and six non-Executive Directors

The Board is satisfied that its current composition and balance between skills, knowledge and experience is complete and appropriate to the requirements of the Trust. 

The day-to-day running of the hospital is carried out by the Leadership Team made up of the Chief Executive, four Executive Directors, and the other members listed below.

Board meeting papers can be downloaded below. Please contact the Corporate Governance office on 020 811 8558 or email foundation.trust@rmh.nhs.uk if you would like to request previous meeting papers.

Chairman

Mr Charles Alexander

  • Chairman
  • Member of Quality, Assurance and Risk Committee
  • Member of Remuneration and Terms of Service Committee
  • Member of Investment Committee

Charles became Chairman of the Trust and The Royal Marsden Cancer Charity on 1 December 2016. Charles’ experience at board level varies across the banking, industry and charitable sectors, including companies such as NM Rothschild, and GE Capital Europe. He is currently a Non-Executive Director of the Department of Culture, Media and Sport and chairs The Countess of Munster Musical Trust as well as the musical charity Opera Rara.

Executive directors

Cally Palmer CBE

  • Chief Executive
  • Member of Quality, Assurance and Risk Committee
  • Member of the Investment Committee
  • Member of the Board of Trustees of The Institute of Cancer Research

Cally Palmer became Chief Executive of The Royal Marsden in 1998, and was awarded Commander of the Order of the British Empire by HM The Queen in 2006 for her contribution to healthcare. She has a Masters degree in Management from the London Business School.

Cally is also a Trustee of The Royal Marsden Cancer Charity and a Member of the Board of the Institute of Cancer Research, London. In October 2015, she was appointed NHS National Cancer Director for NHS England, leading the implementation of the NHS Cancer Taskforce’s five-year strategy for cancer care improvement.

Cally and her team have ensured that The Royal Marsden is the top performing hospitals in England, with the highest ratings in the NHS for quality and efficiency of services. She has advised the Prime Minister and Government on healthcare and national strategy for cancer to ensure all patients have access to the best cancer care available anywhere in the world. 

Dr Liz Bishop

  • Chief Operating Officer/Deputy Chief Executive 
  • Member of Equality and Diversity Committee
  • Member of Quality, Assurance and Risk Committee

Liz Bishop joined The Royal Marsden in January 2010 as Divisional Nurse Director. She was appointed to the Chief Operating Officer in 2013 and in 2016 her role was extended to cover the Deputy Chief Executive portfolio. Before taking on the role of Chief Operating Officer she also spent a period of time as Divisional Director for Cancer Services and as interim Chief Nurse. Liz completed her BSc in Nursing in Scotland in 1986, and her MSc and Doctorate at Surrey University in 2004 and 2009. She has worked in a variety of clinical settings – from surgery to haemato-oncology – in several acute trusts in London, including six years in The Royal Marsden's Bud Flanagan Unit. Prior to rejoining The Royal Marsden she was at Guy’s and St Thomas’ NHS Trust for five years as a Nurse Consultant, Head of Nursing and then General Manager for Oncology.

Mr Marcus Thorman

  • Chief Financial Officer
  • Member of Audit and Finance Committee
  • Member of Investment Committee
  • Member of Quality, Assurance and Risk Committee

Marcus Thorman joined The Royal Marsden as Chief Financial Officer in January 2015 from Imperial College Healthcare NHS Trust. Since joining the NHS through the graduate financial management training scheme he has worked in several provider trusts including mental health & community, acute, teaching and specialist. Marcus has been involved in merging two Trusts, PFI schemes and running a financial shared service for a number of NHS organisations. At Kettering General Hospital, he was Deputy Director of Finance before taking on his first role as a Finance Director overseeing the process for delivering Foundation Trust status in 2008.

Dr Nick van As

  • Medical Director
  • Member of the Quality, Assurance and Risk Committee.

Dr Nick van As has been a Consultant Clinical Oncologist in the Urology Unit at The Royal Marsden for eight years and is our Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. He is also Co-Chair of the UK SBRT Consortium and the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI and he has published numerous papers on these subjects and delivered presentations at international meetings. He is the Chief Investigator for the PACE Trial – an international, randomised controlled trial comparing SBRT to image-guided radiotherapy (IGRT) and surgery for treating prostate cancer.

Eamonn Sullivan

  • Chief Nurse

Eamonn was previously Deputy Chief Nurse at University College London Hospitals, and Head of Nursing, Medicine Board. His corporate responsibilities include patient safety, adult safeguarding, CQUIN and the development of matrons. Before this, Eamonn was Deputy Chief Nurse at Guy’s and St Thomas’ Hospitals, where he also held positions as Head of Performance for Clinical Services and Head of Nursing for Surgery. Eamonn has an MSc in Health Service Development (Critical Care) from Kings College London, he is a Florence Nightingale Leadership Scholar, and he has served in Iraq and Afghanistan in the Army Medical Services Reserves.

Non-executive directors

 

Ian Farmer

  • Chair of Audit and Finance Committee
  • Member of Remuneration and Terms of Service Committee

Ian joined The Royal Marsden as a Non-Executive Director and Chair of the Audit and Finance Committee on 1 April 2014. Ian is a Chartered Accountant and former Chief Executive Officer of Lonmin Plc, the world’s third largest Platinum Group Metals (PGM) mining company.

Professor Paul Workman PhD DSc FMedSci FRSC

  • Chief Executive and President of The Institute of Cancer Research
  • Member of Quality, Assurance and Risk Committee

Professor Paul Workman joined The Royal Marsden as a non-independent Non-Executive Director in July 2014 due to his position as CEO for The Institute of Cancer Research (ICR). Paul is also the Head of its Division of Cancer Therapeutics, Harrap Professor of Pharmacology and Therapeutic and Director of the Cancer Research UK Cancer Therapeutics Unit.

Richard Turnor

  • Member of Audit and Finance Committee
  • Member of Remuneration and Terms of Service Committee
  • Member of Quality, Assurance and Risk Committee

Richard Turnor became a Non- Executive Director in 2009. He was a partner with the international law firm Allen & Overy LLP from 1985 to 2009 before establishing Maurice Turner Gardner LLP in 2010.

Professor Dame Janet Husband

  • Member of Audit and Finance Committee
  • Member of Quality, Assurance and Risk Committee

Professor Dame Janet Husband joined The Royal Marsden as a Non-Executive Director on 1 June 2014. Janet was a Consultant Radiologist and Professor of Diagnostic Radiology at The Royal Marsden and Institute of Cancer Research, as well as former Medical Director of the Trust from 2003 to 2006. Janet became the first female President of the Royal College of Radiologists in 2004.

Having been appointed Officer of the Order of the British Empire (OBE) in 2002, Janet was appointed Dame Commander of the Order of the British Empire (DBE) in 2007. Also in 2007, she was awarded the title of Emeritus Professor of Radiology by the Institute of Cancer Research. In 2010, Janet was appointed Chair of the National Cancer Research Institute and has held a number of non-executive appointments in healthcare, as well as a six-year service as the Specially Appointed Commissioner to The Royal Hospital in Chelsea.

Mark Aedy

Mark has over 35 years of experience in financial services, building and managing investment banking franchises in the UK and internationally. He is currently a Managing Director and Head of EMEA & Asia Investment Banking at Moelis & Company, a global independent investment bank, and is on its Management Committee.

Mark has extensive committee membership experience, which he gained at Bank of America Merrill Lynch, serving on the Global Corporate and Investment Banking Executive Committee and at Merrill Lynch, where he was Head of Investment Banking, EMEA, as well at not-for-profit organisations such as Pilotlight and the Anniversary Committee of the Roundhouse.

Heather Lawrence

Heather is an accomplished former Chief Executive with a track record of service quality improvement. Her last Chief Executive position was at Chelsea and Westminster NHS Foundation Trust from 2000-2012. Since 2012, she has held a number of NED positions and currently serves as Non-Executive Chair of the London Ambulance Service, with the task of steering the Trust out of special measures.

She is a nurse by background and has an impressive track record of success in both her Executive and NED roles. Heather will bring her patient-focused clinical expertise to the role of the Non-Executive Director.

Professor Martin Elliott

Martin is a Paediatric Cardiothoracic Surgeon who has spent the majority of his career at Great Ormond Street Hospital, where he held several clinical leadership positions including co-Medical Director from 2010-2015. He also holds a Chair in Paediatric Cardiothoracic Surgery at University College London, and is the 37th Professor of Physic at Gresham College.

He is an established clinical leader with strong understanding of the particular challenges and opportunities facing specialist Trusts. As co-Medical Director, Martin led on quality and safety, digital technology and clinical strategy development.

Other members of the Leadership Team

Nicky Browne, Director of Transformation & Charity Liaison

Jon Spencer, Divisional Director of Clinical Services

Professor David Cunningham, Director of Clinical Research

Antonia Dalmahoy, Director of The Royal Marsden Cancer Charity

Anne Howers, Clinical Director for Sutton Community Services

Dr Imogen Locke, Lead for Clinical Oncology

Shams Maladwala, Managing Director Private Care

Steven Francis, Director of Performance & Information 

Professor David Nicol, Chief of Surgery

Rachael Reeve, Director of Marketing and Communications

Nina Singh, Director of Workforce

Sunil Vyas, Director of Projects and Estates

Dr Tim Wigmore, Chief Clinical Information Officer

Sarah Clarke, Director of Cancer Services

Board and Leadership Team Register of Interests